Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.

Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R.

J Pediatr. 2008 Apr;152(4):582-4. doi: 10.1016/j.jpeds.2007.12.020.

2.

Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.

Ray AS, Fordyce MW, Hitchcock MJ.

Antiviral Res. 2016 Jan;125:63-70. doi: 10.1016/j.antiviral.2015.11.009. Epub 2015 Nov 27. Review.

3.

Experience with tenofovir disoproxil fumarate for antiretroviral therapy.

Stephan C.

Expert Opin Pharmacother. 2008 May;9(7):1197-209. doi: 10.1517/14656566.9.7.1197. Review.

PMID:
18422476
5.

Review of tenofovir use in HIV-infected children.

Aurpibul L, Puthanakit T.

Pediatr Infect Dis J. 2015 Apr;34(4):383-91. doi: 10.1097/INF.0000000000000571. Review.

PMID:
25247583
6.

Bone health in children and adolescents with perinatal HIV infection.

Puthanakit T, Siberry GK.

J Int AIDS Soc. 2013 Jun 18;16:18575. doi: 10.7448/IAS.16.1.18575. Review.

7.

Osteoporosis and bone health in HIV.

Powderly WG.

Curr HIV/AIDS Rep. 2012 Sep;9(3):218-22. doi: 10.1007/s11904-012-0119-7. Review.

PMID:
22581359
8.

Bone changes and fracture risk in individuals infected with HIV.

Warriner AH, Mugavero MJ.

Curr Rheumatol Rep. 2010 Jun;12(3):163-9. doi: 10.1007/s11926-010-0099-9. Review.

PMID:
20425517
9.

Pediatric HIV infection and bone health: an emerging challenge.

Mora S, Zamproni I, Zuccotti G, Vigano A.

Front Biosci (Elite Ed). 2010 Jun 1;2:1265-74. Review.

PMID:
20515800

Supplemental Content

Support Center